{"id":"W4399700479","doi":"10.1016/j.jval.2024.03.691","title":"EE395 Cost-Effectiveness Analysis of Nivolumab Plus Relatlimab (NIVO+RELA) Versus Current Standard of Care (SOC) for Patients with Unresectable or Metastatic Melanoma in Canada","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"","keywords":"Nivolumab; Medicine; Metastatic melanoma; Oncology; Internal medicine; Standard of care; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002161663,0.0007772556,0.001607244,0.0009297065,0.0005688998,0.00152982,0.001172123,0.0006819379,0.003950406],"category_scores_gemma":[0.006776369,0.0003861534,0.004197338,0.001554263,0.000550898,0.0005076083,0.000654584,0.00145334,0.0001565802],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.04693462,"about_ca_system_score_gemma":0.0357118,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9030968,"about_ca_topic_score_gemma":0.922452,"domain_scores_codex":[0.9981983,0.0006969686,0.0001227635,0.000162084,0.000365148,0.0004546785],"domain_scores_gemma":[0.9978651,0.0006431997,0.0002720561,0.00005752004,0.0005232386,0.0006388171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.3475288,0.005260375,0.1598437,0.01015099,0.03586036,0.00072619,0.0003828196,0.1717211,0.002357307,0.006717414,0.02948151,0.2299694],"study_design_scores_gemma":[0.1001361,0.02993784,0.597817,0.004250309,0.03928337,0.000663294,0.001194536,0.1991522,0.001676485,0.002450823,0.02298091,0.0004571496],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9546213,0.01901122,0.0007296496,0.002456881,0.0002421246,0.001134552,0.0133843,0.00005854736,0.008361454],"genre_scores_gemma":[0.9912295,0.002399909,0.0006138993,0.0003409882,0.00004678629,0.0001284111,0.003855335,0.00001121781,0.001373992],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0969032,"threshold_uncertainty_score":0.3405361,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2754352336219331,"score_gpt":0.4260363249080076,"score_spread":0.1506010912860745,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}